CanSino Biologics Inc. (6185.HK) HKSE

Currency In HKD

Key Executives

Name	Title	Pay	Year Born
Xuefeng Yu	Co-Founder, Executive Chairman, Chief Executive Officer & GM	4.43M	1964
Shou-Bai Chao	Chief Operating Officer, Deputy GM & Executive Director	2.95M	1963
Jing Wang	Chief Commercial Officer, Deputy GM & Executive Director	3.88M	1981
Dongxu Qiu	Co-Founder, Executive Vice President & Deputy GM	4.11M	1960
Tao Zhu	Co-Founder, Deputy GM & Chief Scientific Officer	4.86M	1973
Chunlin Xin	Senior Director of New Technology Department	0	N/A
Jin Cui	Board Secretary	0	1987
Ming King Chiu FCIS	Joint Company Secretary	0	1977
Yonghui Wu	Vice President of Marketing	0	N/A
Bei Bei Gao	Accounting Supervisor	0	N/A
Ming Liu	Acting Head of Finance	0	N/A

Name

Title

Pay

Year Born

Xuefeng Yu

Co-Founder, Executive Chairman, Chief Executive Officer & GM

4.43M

1964

Shou-Bai Chao

Chief Operating Officer, Deputy GM & Executive Director

2.95M

1963

Jing Wang

Chief Commercial Officer, Deputy GM & Executive Director

3.88M

1981

Dongxu Qiu

Co-Founder, Executive Vice President & Deputy GM

4.11M

1960

Tao Zhu

Co-Founder, Deputy GM & Chief Scientific Officer

4.86M

1973

Chunlin Xin

Senior Director of New Technology Department

N/A

Jin Cui

Board Secretary

1987

Ming King Chiu FCIS

Joint Company Secretary

1977

Yonghui Wu

Vice President of Marketing

N/A

Bei Bei Gao

Accounting Supervisor

N/A

Ming Liu

Acting Head of Finance

N/A

Description

CanSino Biologics Inc., a company established in 2009 and headquartered in Tianjin, People's Republic of China, is dedicated to the research, development, manufacturing, and commercialization of vaccines throughout China. Its existing portfolio includes significant vaccines such as Convidecia and Ad5-nCoV for Inhalation, both designed to combat recombinant novel coronavirus disease. The company has also developed Ad5-EBOV, an effective vaccine against the Ebola virus, and offers MCV2 and MCV4 vaccines for preventing N. meningitides infections. A substantial portion of its pipeline is currently undergoing Phase I clinical trials. This includes DTcP vaccines for infants and a DTcP Booster, both aimed at providing enhanced protection against pertussis after initial immunization. Also in Phase I are PBPV, a serotype-independent protein-based pneumococcal vaccine; PCV13i, a pneumococcal conjugate vaccine; and a TB Booster vaccine intended for the BCG-immunized population. Furthermore, CanSino is developing a Tdcp vaccine specifically for adolescents and adults to address pertussis. Beyond these clinical-stage candidates, the company maintains a robust pipeline of preclinical products. This includes a DTcP-Hib Combo vaccine, CSB012 for adenovirus, CSB013 targeting the ZIKA virus, CSB015 for meningitis, CSB016 for shingles, and CSB107 against polio.